View in EDS HTML Full Text PDF Full Text

METTL7A inhibits progression of colorectal cancer through the SREBP1 / FDFT1 / SQLE / CYP51A1 / cholesterol metabolic pathway.

Saved in:
Bibliographic Details
Title: METTL7A inhibits progression of colorectal cancer through the SREBP1 / FDFT1 / SQLE / CYP51A1 / cholesterol metabolic pathway.
Authors: Li S; State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing, 100050, China.; Beijing Key Laboratory of Innovative Drug Discovery and Polymorphic Drug ability Research for Cerebrovascular Diseases, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, China.; Department of Pharmacy, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, 010000, China., Chi X; State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing, 100050, China.; Beijing Key Laboratory of Innovative Drug Discovery and Polymorphic Drug ability Research for Cerebrovascular Diseases, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, China., Li X; State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing, 100050, China.; Beijing Key Laboratory of Innovative Drug Discovery and Polymorphic Drug ability Research for Cerebrovascular Diseases, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, China.; School of Clinical Pharmacy, Shenyang Pharmaceutical University, Shenyang, 110000, China., Li W; State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing, 100050, China.; Beijing Key Laboratory of Innovative Drug Discovery and Polymorphic Drug ability Research for Cerebrovascular Diseases, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, China., Yang H; State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing, 100050, China.; Beijing Key Laboratory of Innovative Drug Discovery and Polymorphic Drug ability Research for Cerebrovascular Diseases, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, China., Cao W; State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing, 100050, China.; Beijing Key Laboratory of Innovative Drug Discovery and Polymorphic Drug ability Research for Cerebrovascular Diseases, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, China., Zhao Y; State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing, 100050, China.; Beijing Key Laboratory of Innovative Drug Discovery and Polymorphic Drug ability Research for Cerebrovascular Diseases, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, China.; School of Pharmacy, Henan University, Kaifeng, 475004, China., Zhang X; State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing, 100050, China.; Beijing Key Laboratory of Innovative Drug Discovery and Polymorphic Drug ability Research for Cerebrovascular Diseases, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, China., Meng R; State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing, 100050, China.; Beijing Key Laboratory of Innovative Drug Discovery and Polymorphic Drug ability Research for Cerebrovascular Diseases, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, China.; Shanxi University, Taiyuan, 030006, China., Du G; State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing, 100050, China.; Beijing Key Laboratory of Innovative Drug Discovery and Polymorphic Drug ability Research for Cerebrovascular Diseases, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, China., Zhang D; State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing, 100050, China. danzhang@imm.ac.cn.; Department of Pharmacology, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, China. danzhang@imm.ac.cn., Wang J; State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing, 100050, China. wjh@imm.ac.cn.; Beijing Key Laboratory of Innovative Drug Discovery and Polymorphic Drug ability Research for Cerebrovascular Diseases, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, China. wjh@imm.ac.cn.
Source: Cellular oncology (Dordrecht, Netherlands) [Cell Oncol (Dordr)] 2026 Apr 20; Vol. 49 (3). Date of Electronic Publication: 2026 Apr 20.
Publication Type: Journal Article
Journal Info: Publisher: Springer Country of Publication: Netherlands NLM ID: 101552938 Publication Model: Electronic Cited Medium: Internet ISSN: 2211-3436 (Electronic) Linking ISSN: 22113428 NLM ISO Abbreviation: Cell Oncol (Dordr) Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:2211-3436
DOI:10.1007/s13402-026-01209-2